Vinpocetine has been investigated for the treatment of Epilepsy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Vinpocetine may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Vinpocetine may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Vinpocetine. |
| Buprenorphine | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Hydrocodone | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Magnesium sulfate | The therapeutic efficacy of Vinpocetine can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Vinpocetine may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Mirtazapine | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Orphenadrine | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Pramipexole | Vinpocetine may increase the sedative activities of Pramipexole. |
| Ropinirole | Vinpocetine may increase the sedative activities of Ropinirole. |
| Rotigotine | Vinpocetine may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Vinpocetine. |
| Sodium oxybate | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Thalidomide | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Mefloquine | The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Vinpocetine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Vinpocetine may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Cimetidine | The serum concentration of Vinpocetine can be increased when it is combined with Cimetidine. |
| Clopidogrel | The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Vinpocetine. |
| Efavirenz | The serum concentration of Vinpocetine can be decreased when it is combined with Efavirenz. |
| Melatonin | The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Melatonin. |
| Nafcillin | The therapeutic efficacy of Vinpocetine can be decreased when used in combination with Nafcillin. |
| Nitroprusside | Vinpocetine may increase the hypotensive activities of Nitroprusside. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Vinpocetine. |
| Dantrolene | The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Vinpocetine. |
| Lithium citrate | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Lithium citrate. |
| Lithium carbonate | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Lithium carbonate. |
| Lithium hydroxide | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Lithium hydroxide. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Vinpocetine. |
| Boceprevir | The serum concentration of Vinpocetine can be increased when it is combined with Boceprevir. |
| Ethanol | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Vinpocetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Sibutramine. |
| Escitalopram | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Vinpocetine is combined with Alaproclate. |
| Ibutilide | Ibutilide may increase the arrhythmogenic activities of Vinpocetine. |
| Adenosine | Adenosine may increase the arrhythmogenic activities of Vinpocetine. |
| Levosimendan | Levosimendan may increase the arrhythmogenic activities of Vinpocetine. |
| Procainamide | Procainamide may increase the arrhythmogenic activities of Vinpocetine. |
| Tocainide | Tocainide may increase the arrhythmogenic activities of Vinpocetine. |
| Flecainide | Flecainide may increase the arrhythmogenic activities of Vinpocetine. |
| Encainide | Encainide may increase the arrhythmogenic activities of Vinpocetine. |
| Ajmaline | Ajmaline may increase the arrhythmogenic activities of Vinpocetine. |
| Aprindine | Aprindine may increase the arrhythmogenic activities of Vinpocetine. |
| Azimilide | Azimilide may increase the arrhythmogenic activities of Vinpocetine. |
| Tedisamil | Tedisamil may increase the arrhythmogenic activities of Vinpocetine. |
| Vernakalant | Vernakalant may increase the arrhythmogenic activities of Vinpocetine. |
| Cariporide | Cariporide may increase the arrhythmogenic activities of Vinpocetine. |
| Xylometazoline | Xylometazoline may increase the arrhythmogenic activities of Vinpocetine. |
| Sparteine | Sparteine may increase the arrhythmogenic activities of Vinpocetine. |
| Fasudil | Fasudil may increase the arrhythmogenic activities of Vinpocetine. |
| Carteolol | Vinpocetine may increase the arrhythmogenic activities of Carteolol. |
| Metipranolol | Vinpocetine may increase the arrhythmogenic activities of Metipranolol. |
| Simendan | Vinpocetine may increase the arrhythmogenic activities of Simendan. |
| Spiradoline | Vinpocetine may increase the arrhythmogenic activities of Spiradoline. |
| Pilsicainide | Vinpocetine may increase the arrhythmogenic activities of Pilsicainide. |
| Cicletanine | Vinpocetine may increase the arrhythmogenic activities of Cicletanine. |
| Cibenzoline | Vinpocetine may increase the arrhythmogenic activities of Cibenzoline. |
| Nizofenone | Vinpocetine may increase the arrhythmogenic activities of Nizofenone. |
| Prajmaline | Vinpocetine may increase the arrhythmogenic activities of Prajmaline. |
| Tiracizine | Vinpocetine may increase the arrhythmogenic activities of Tiracizine. |
| Ethacizine | Vinpocetine may increase the arrhythmogenic activities of Ethacizine. |
| Lorajmine | Vinpocetine may increase the arrhythmogenic activities of Lorajmine. |
| Bunaftine | Vinpocetine may increase the arrhythmogenic activities of Bunaftine. |
| Lorcainide | Vinpocetine may increase the arrhythmogenic activities of Lorcainide. |
| Hydroquinine | Vinpocetine may increase the arrhythmogenic activities of Hydroquinine. |
| Bioallethrin | Vinpocetine may increase the arrhythmogenic activities of Bioallethrin. |
| Fosfructose | Vinpocetine may increase the arrhythmogenic activities of Fosfructose. |
| Hydroquinidine | Vinpocetine may increase the arrhythmogenic activities of Hydroquinidine. |
| SOR-C13 | Vinpocetine may increase the arrhythmogenic activities of SOR-C13. |
| Digoxin | Digoxin may increase the arrhythmogenic activities of Vinpocetine. |
| Acetyldigitoxin | Acetyldigitoxin may increase the arrhythmogenic activities of Vinpocetine. |